Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Basal-Like Breast Carcinoma|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Hereditary Breast and Ovarian Cancer Syndrome|Ovarian Carcinoma|Pancreatic Carcinoma|Progesterone Receptor Negative|Prostate Carcinoma|Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Solid Neoplasm|Triple-Negative Breast Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Veliparib
Sponsor: National Cancer Institute (NCI)